Key Highlights

  • Net loss narrowed 30% to $14.0 million from $20.1 million in FY25, with net operating cash outflow down 37% to $7.8 million.
  • Revenue declined 7% to $14.8 million from $15.9 million, which the company attributed to a competitive, price-sensitive market and a delayed Australian respiratory season.
  • An organisational restructuring completed in April 2026 is expected to deliver annual cost savings of $5 million from FY2027 onwards.
  • A ten-year Supply agreement was signed with Hvidovre Hospital in Denmark, with the first commercial order received and testing commenced in August 2026.

Net Loss Narrows Amid Restructuring

Genetic Signatures Limited (ASX:GSS) reported its FY2026 financial results and market update, with net loss narrowing 30% to $14.0 million from $20.1 million in FY25. Net operating cash outflow declined 37% to $7.8 million from $12.3 million. Shares in Genetic Signatures traded at $0.075 on the ASX at the time of the announcement, up 2.74 percent, or $0.002, on the day.

Revenue Decline in a Competitive Market

Revenue for FY26 was $14.8 million, down 7% from $15.9 million in FY25, which the company attributed to a competitive, price-sensitive market and a delayed Australian respiratory season. Gross Profit declined to $6.3 million from $8.8 million, reflecting the lower Revenue combined with a higher cost of materials, which rose to $8.5 million from $7.1 million. Other income increased to $4.5 million from $3.9 million, while interest revenue declined to $1.0 million from $1.6 million.

Cost Reductions from Restructuring

Employee benefits expense decreased 16% to $13.4 million from $16.1 million, which the company said reflected the early results of its FY2026 organisational restructuring, completed in April 2026 and expected to deliver annual cost savings of $5 million from FY2027 onwards. Impairment expenses declined to $2.1 million from $7.0 million, while other expenses fell to $8.3 million from $8.9 million. The company maintained a cash balance of $22.1 million in cash and term deposits as at 30 June 2026, with no debt.

New Supply Agreements

The company announced a ten-year supply agreement signed with Hvidovre Hospital in Denmark, with the first commercial order received and testing commenced in August 2026. The company also signed a long-term supply agreement in Australia that includes built-in annual growth provisions. Alongside these agreements, the company appointed a new CEO and completed a comprehensive organisational review, resulting in the release of the company's growth strategy.

Growth Strategy Priorities

The company outlined several priorities as part of its growth strategy, including growing revenue on the stabilised Business through existing and new customer relationships supported by long-term supply agreements, focusing on profitability through contracts designed to improve unit Economics with Margin discipline, continuing disciplined Capital deployment where spending is justified against expected return and risk, outsourcing product development to limit product risk associated with non-core Research and Development activities, and continuing to focus on manufacturing, product development, distribution and instrumentation partnerships alongside synergistic corporate partnerships. The company also identified new growth opportunities in the APAC and EMEA regions through infection prevention and control in hospitals, while Australian revenue is expected to grow through product extensions.

Conclusion

Genetic Signatures reported a significantly narrower net loss for FY26, supported by cost reductions from its completed organisational restructuring and improved operating cash flow, even as revenue declined amid competitive market pressures and a delayed respiratory season in Australia. The signing of a ten-year supply agreement with Hvidovre Hospital in Denmark, alongside a new long-term Australian supply agreement, provides the company with a foundation for revenue growth going into FY27, supported by the expected $5 million in annual cost savings from the completed restructuring and a strong Balance Sheet with no debt.